0001213900-25-061364.txt : 20250703 0001213900-25-061364.hdr.sgml : 20250703 20250703133030 ACCESSION NUMBER: 0001213900-25-061364 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250630 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250703 DATE AS OF CHANGE: 20250703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pluri Inc. CENTRAL INDEX KEY: 0001158780 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 980351734 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31392 FILM NUMBER: 251104832 BUSINESS ADDRESS: STREET 1: MATAM ADVANCED TECHNOLOGY PARK STREET 2: BUILDING NO. 5 CITY: HAIFA STATE: L3 ZIP: 3508409 BUSINESS PHONE: 972-74-710-7171 MAIL ADDRESS: STREET 1: MATAM ADVANCED TECHNOLOGY PARK STREET 2: BUILDING NO. 5 CITY: HAIFA STATE: L3 ZIP: 3508409 FORMER COMPANY: FORMER CONFORMED NAME: PLURISTEM THERAPEUTICS INC DATE OF NAME CHANGE: 20071228 FORMER COMPANY: FORMER CONFORMED NAME: PLURISTEM LIFE SYSTEMS INC DATE OF NAME CHANGE: 20030701 FORMER COMPANY: FORMER CONFORMED NAME: AI SOFTWARE INC DATE OF NAME CHANGE: 20010906 8-K 1 ea0248143-8k_pluri.htm CURRENT REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 3, 2025 (June 30, 2025)

PLURI INC.

(Exact Name of Registrant as Specified in Its Charter)

Nevada		001-31392		98-0351734
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

MATAM Advanced Technology Park
Building No. 5
Haifa, Israel		3508409
(Address of Principal Executive Offices)		(Zip Code)

011 972 74 710 8600

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, par value $0.00001 per share		PLUR		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.

On June 30, 2025, Pluri Inc. (the “Company”), held its 2025 Annual Meeting of Shareholders (the “2025 Annual Meeting”). As a result of the voting outcome at the 2025 Annual Meeting, Mr. Doron Birger was not re-elected to the Company’s Board of Directors (the “Board”) and therefore ceased to serve as a director and as a member of the respective committees on which he serves, effective immediately. Prior to his departure, Mr. Birger was an independent director, Chairman of the Audit Committee, and the sole member of the Investment Committee.

On June 30, 2025, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) that due to Mr. Birger’s departure, the Company is no longer in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires the Audit Committee to be comprised of at least three independent directors. On July 2, 2025, the Company received a letter from the Listing Qualifications Department of Nasdaq, notifying the Company that consistent with Listing Rule 5605(c)(4), Nasdaq will provide the Company a cure period to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A), which will expire on the earlier of (i) the Company’s next annual meeting of shareholders or June 30, 2026, or (ii) if the Company’s next annual meeting of shareholders is held before December 29, 2025, then the Company must evidence compliance no later than June 30, 2026. The Company intends to appoint an additional independent director to the Board and the Audit Committee prior to the expiration of the applicable cure period.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 30, 2025, the Company held its 2025 Annual Meeting. The results of shareholders voting at the 2025 Annual Meeting are set forth below:

Proposal No. 1 - Election of Directors

The shareholders cast the following votes for the following individuals nominated as directors of the Company to hold office until the next annual meeting of shareholders and until their successors shall have been duly elected and qualified.

Director Name		For				Against				Abstain				Broker Non-Votes
Zami Aberman			3,655,962				37,872				297,831				778,972

Doron Birger			1,270,717				2,720,350				598				778,972

Rami Levi			3,977,009				13,754				901				778,972

Maital Shemesh-Rasmussen			3,974,994				15,840				831				778,972

Yaky Yanay			3,930,082				60,997				598				778,972

Alexandre Weinstein			3,942,043				49,033				601				778,972

1

Proposal No. 2 - Ratification of the selection of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as independent registered public accounting firm of the Company for the fiscal year ending June 30, 2025.

For		Against		Abstain		Broker Non-Votes
5,164,886		16,289		8,735		N/A

Proposal No. 3 – To Consider and approve the Company’s 2016 Equity Compensation Plan.

For		Against		Abstain		Broker Non-Votes
3,914,964		69,257		7,443		778,972

Proposal No. 4 – To consider and approve, by a nonbinding advisory vote, the compensation of the Company’s named executive officers as described in the accompanying proxy statement.

For		Against		Abstain		Broker Non-Votes
3,919,160		66,894		5,615		778,972

Proposal No. 5 – To recommend, by a nonbinding advisory vote, the frequency (every one, two or three years) of future advisory votes of shareholders on the compensation of our named executive officers.

1 Year		2 Years		3 Years		Abstain		Broker Non-Votes
1,275,471		2,403,566		8,025		304,630		778,972

In accordance with the shareholder voting results, in which every “Two Years” received the highest number of votes cast on the frequency proposal, and the Company’s Board of Directors’ recommendation in the proxy statement for the 2025 Annual Meeting, the Company’s Board of Directors has determined that future shareholder advisory (non-binding) votes on the compensation of the Company’s named executive officers will occur every two years. Accordingly, the next shareholder advisory (non-binding) vote on executive compensation will be held at the Company’s 2027 annual meeting of shareholders.

Proposal No. 6 – To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the exercise of common warrants and pre-funded warrants to purchase up to 1,086,768 common shares, which were issued pursuant to a Securities Purchase Agreement dated January 23, 2025, as amended by an Amendment to the Securities Purchase Agreement dated April 25, 2025 between the Company and a company wholly beneficially owned by Mr. Alexandre Weinstein, relating to a private placement offering.

For		Against		Abstain		Broker Non-Votes
3,530,251		47,936		5,668		778,972

The vote total set forth above with respect to Proposal No. 6 excludes shares beneficially owned by Mr. Alexandre Weinstein, which were not counted for purposes of such proposal, as the securities underlying the exercise of warrants and pre-funded warrants are to be issued pursuant to a private placement between the Company and an entity wholly beneficially owned by Mr. Alexandre Weinstein.

The results reported above are final voting results.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PLURI INC.

Date: July 3, 2025	By:	/s/ Liat Zalts
	Name:	Liat Zalts
	Title:	Chief Financial Officer

3

EX-101.SCH 2 plur-20250630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 plur-20250630_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 plur-20250630_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Jun. 30, 2025
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2025
Entity File Number	001-31392
Entity Registrant Name	PLURI INC.
Entity Central Index Key	0001158780
Entity Tax Identification Number	98-0351734
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	MATAM Advanced Technology Park
Entity Address, Address Line Two	Building No. 5
Entity Address, City or Town	Haifa
Entity Address, Country	IL
Entity Address, Postal Zip Code	3508409
City Area Code	011
Local Phone Number	972 74 710 8600
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Shares, par value $0.00001 per share
Trading Symbol	PLUR
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://pluri-biotech.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea0248143-8k_pluri.htm plur-20250630.xsd plur-20250630_lab.xml plur-20250630_pre.xml http://xbrl.sec.gov/dei/2025 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0248143-8k_pluri.htm": { "nsprefix": "PLUR", "nsuri": "http://pluri-biotech.com/20250630", "dts": { "inline": { "local": [ "ea0248143-8k_pluri.htm" ] }, "schema": { "local": [ "plur-20250630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "labelLink": { "local": [ "plur-20250630_lab.xml" ] }, "presentationLink": { "local": [ "plur-20250630_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2025": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 23 }, "report": { "R1": { "role": "http://pluri-biotech.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2025-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0248143-8k_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0248143-8k_pluri.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentDescription", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AnnualInformationForm", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CountryRegion", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodStartDate", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentQuarterlyReport", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine3", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPrimarySicNumber", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Extension", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12gTitle", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityReportingObligation", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0001213900-25-061364-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-25-061364-xbrl.zip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end XML 14 ea0248143-8k_pluri_htm.xml IDEA: XBRL DOCUMENT 0001158780 2025-06-30 2025-06-30 iso4217:USD shares iso4217:USD shares false 0001158780 8-K 2025-06-30 PLURI INC. NV 001-31392 98-0351734 MATAM Advanced Technology Park Building No. 5 Haifa IL 3508409 011 972 74 710 8600 false false false false Common Shares, par value $0.00001 per share PLUR NASDAQ false